Physician profile
James M Learner
NPI 1053422006
$1,728.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $178 · 2021: $181 · 2022: $111 · 2023: $126 · 2024: $26.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $711.97 | 2019-2022 | |
| Astellas Pharma US INC | $160.87 | 2019-2023 | Myrbetriq |
| Abbott Laboratories | $137.98 | 2023-2024 | Freestyle Libre 3, Agilis |
| Pfizer INC. | $127.39 | 2019 | |
| Novo Nordisk INC | $108.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $99.21 | 2019-2020 | |
| Amgen INC. | $82.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.27 | 2019 | |
| Merck Sharp & Dohme LLC | $46.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.43 | 2019 | |
| Glaxosmithkline, LLC. | $17.12 | 2019 | |
| Biogen, INC. | $13.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.56 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Learner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.